However, a new CAR-T cell therapy called obecabtagene autoleucel could change this situation. CAR-T therapy (Chimeric Antigen ...

Glioblastoma (GBM) is the most common kind of malignant brain tumor in adults. In recent years, the tumor microenvironment ...

Engineered receptors could lead to more precisely targeted, effective cancer therapies with fewer side effects than existing ...

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

2seventy Bio focuses on pioneering cell and gene therapies. Its lead product, Abecma, is a chimeric antigen receptor (CAR) ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).

The process begins with the collection of a patient’s T cells. Then these T cells are genetically modified to express ...

Marker Therapeutics was awarded a $2 million grant from NIH Small Business Innovation Research Program (SBIR) to support the clinical investigation of MT-601 in patients with lymphoma who have ...